In response to the unprecedented demand for its blockbuster obesity drugs, Ozempic and Wegovy, Danish pharmaceutical giant Novo Nordisk is eyeing the establishment of a 'mega manufacturing facility' outside of Dublin. 

The company has submitted a planning application for a sprawling campus in Clondalkin, covering 147,192 square meters and potentially generating up to 1,100 jobs in the region.

According to sources, Novo Nordisk's move is driven by the overwhelming success of Ozempic and Wegovy, which has propelled the century-old company to become Europe's most valuable listed company, surpassing Denmark's domestic economy in market capitalization. The surge in demand has strained the company's manufacturing capacity, necessitating the expansion.

The proposed investment is expected to exceed EUR 2 billion, based on comparable developments by the company. The project is anticipated to take between 18 and 24 months to complete, with full operational capability expected by 2026.

If approved, the Dublin development will encompass three filling and packaging manufacturing facilities, a warehouse building, two assembly and packaging facilities, an administration building, and a laboratory.